de Joode, K.
van de Geer, W. S.
van Leenders, G. J. L. H.
Hamberg, P.
Westgeest, H. M.
Beeker, A.
Oosting, S. F.
van Rooijen, J. M.
Beerepoot, L. V.
Labots, M.
Mathijssen, R. H. J.
Lolkema, M. P.
Cuppen, E.
Sleijfer, S.
van de Werken, H. J. G.
van der Veldt, A. A. M.
Article History
Received: 23 December 2022
Accepted: 27 June 2023
First Online: 3 July 2023
Competing interests
: K.J. declares travel expenses from Ipsen, outside the submitted work; P.H. declares consultancy roles for Astellas, MSD, Ipsen, Pfizer, AstraZeneca, and Bristol-Myers Squibb, all outside the submitted work; H.M.W. declares honoraria from Roche and Astellas and travel expenses from Ipsen and Astellas, all outside the submitted work; S.F.O declares research grants from Novartis, Pfizer and Celldex Therapeutics and advisory board for Bristol Myers Squibb (all paid to the institution); M.L. declares speakers fee of BMS and advisory board of MSD, both paid to institution; R.H.J.M. declares speakers fee from Novartis and advisory role for Servier, patency from Pamgene, and investigator-initiated research (paid to institution) from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Pamgene, Pfizer, Novartis, Roche, Sanofi, Servier, all outside the submitted work; M.P.L. declares advisory board for Amgen, Astellas, Astra Zeneca, Bayer, INCa, Janssen Cilag BV, MSD, Novartis, Pfizer, Roche, Sanofi, Servier, consulting role for Julius Clinical and Research Grants (paid to institution) from Astellas, Janssen, MSD, Sanofi, all outside the submitted work; H.J.G.W. declares speakers honoraria from Bayer, Depositary receipts for shares from Cergentis B.V. all outside the submitted work; A.A.M.V. reports advisory board (all paid to institution) of BMS, MSD, Merck, Pfizer, Ipsen, Eisai, Pierre Fabre, Roche, Novartis, Sanofi, all outside the submitted work. All other authors declare no competing interests.